A Study of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis (PALIZADE)

Key Inclusion Criteria:

• Body mass index of ≥18 kg/m^2

• eGFR ≥30 mL/min/1.73 m^2

• Unequivocally positive ANA test result and/or a positive anti-dsDNA serum antibodytest

• Diagnosis of LN according to 2003 or 2018 ISN/RPS criteria and confirmed by renalbiopsy performed within 12 months prior to Screening.

• UPCR ≥1.0 (Class III/IV +/-V) or UPCR ≥2.0 (Class V)

• Adequate hematologic, hepatic, and renal function

Key Exclusion Criteria:

• Current or medical history of:

• Central nervous system manifestations of SLE

• Overlapping autoimmune condition that may affect study assessments/outcomes

• Antiphospholipid syndrome with history of thromboembolic event of within the 52weeks prior to Screening

• Thrombocytopenia or at high risk for developing clinically significant bleedingor organ dysfunction requiring therapies (i.e., plasmapheresis or acute bloodor platelet transfusions

• Solid organ transplant or planned transplant during study

• Malignancy of any type, with exceptions for non-melanoma skin cancers andcertain cancers >5 years ago

• Has received dialysis within the 52 weeks prior to Screening

• Positive test at Screening for HIV, hepatitis B/C

• Known intolerance to MMF or equivalent and corticosteroids